<DOC>
	<DOCNO>NCT01146353</DOCNO>
	<brief_summary>Pharmacokinetics peramivir well characterize patient undergo continuous renal replacement therapy CRRT - either Continuous veno-venous hemofiltration ( CVVH ) +/- dialysis ( CVVHD ) . CRRT commonly utilize hospital setting patient acute kidney injury metabolic correction , slow continuous fluid removal , maintain hemodynamic stability . CRRT commonly alters drug disposition clearance , dose regimen often need alteration patient receive CRRT . Doses required generate predictable serum concentration calculate known patient parameter replacement fluid dialysate flow rate , sieve coefficient , desire serum concentration . However , pharmacokinetic study must perform CRRT patient generate drug removal constant sieve coefficient . Of note , clearance drug conventional hemodialysis use extrapolate clearance CRRT secondary difference ultrafiltration rate dialysis membrane . The investigator propose open label study obtain peramivir pharmacokinetics patient undergo CRRT .</brief_summary>
	<brief_title>Pharmacokinetic Assessment Peramivir Hospitalized Adults Undergoing Continuous Renal Replacement Therapy</brief_title>
	<detailed_description>This study close . No patient enrol peramivir EUA rescind .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Inclusion Criteria Patient hospitalize undergo continuous renal replacement therapy ( CRRT ) result clinical management patient ( i.e . CRRT initiate purpose study ) . Patient receive peramivir positive rapid antigen test influenza basis clinical suspicion high local epidemiological prevalence H1N1 disease . Patient CRRT blood flow rate great equal 100 mL/min ultrafiltrate +/ dialysis flow rate great equal 3000mL/hr , The patient anticipate require CRRT peramivir treatment full 24 hour ( i.e . life expectancy le 24 hour ) . Exclusion Criteria The patient receive great 5 dos peramivir . The subject preexisting illness , opinion investigator , would place subject unreasonably increase risk participation study . The patient receive CRRT utilize premembrane dilution method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>peramivir</keyword>
	<keyword>CVVH</keyword>
	<keyword>CRRT</keyword>
	<keyword>CVVHD</keyword>
	<keyword>influenza</keyword>
	<keyword>sieve coefficient</keyword>
	<keyword>clearance</keyword>
</DOC>